NEW YORK, NY--(Marketwired - May 11, 2015) - Kadmon Corporation, LLC, today announced that the Company's research on the role of ROCK2 (Rho-associated coiled-coil kinase 2) in regulating immune response was recognized by World Biomedical Frontiers for its "innovation and potential for significant impact." The data were previously published in Proceedings of the National Academy of Sciences in November 2014.
"Kadmon's research reveals ROCK2 as a therapeutic target with wide-ranging potential, supporting the rationale for our clinical and preclinical programs in this area," said Harlan W. Waksal, M.D., President and CEO of Kadmon. The Company is developing KD025, an orally bioavailable, potent and highly selective inhibitor of ROCK2, currently in a Phase 2 trial in psoriasis. In addition, Kadmon is developing a suite of ROCK2-specific compounds, including blood-brain barrier penetrant compounds, to permit the optimal pairing of inhibitors with a variety of autoimmune, fibrotic and neurodegenerative disease indications.
"We are pleased to have our ROCK2 research recognized as we continue our ongoing Phase 2 study of KD025 in psoriasis and prepare to initiate trials of ROCK2 inhibition in other indications," Dr. Waksal added.
World Biomedical Frontiers is a website featuring research with significant potential to improve health or to treat or prevent disease. The article, titled "Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism," is featured in World Biomedical Frontiers' section on arthritis for its importance and relevance in that disease area. The article is available here: http://biomedfrontiers.org/arthritis-2015-5-1/.
About KD025
KD025 is Kadmon's Phase 2, orally bioavailable, potent and highly selective inhibitor of ROCK2 (Rho-associated coiled-coil kinase 2), a signaling pathway involved in regulating immune response. Preclinical studies have shown that ROCK2 inhibition with KD025 down-regulates the secretion of pro-inflammatory cytokines including IL-21 and IL-17, and concurrently up-regulates the suppressive function of regulatory T cells (Treg), helping to resolve inflammation with a minimal effect on the rest of the immune response.
About Kadmon Corporation
Kadmon Corporation, LLC, is a vertically integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in autoimmune and fibrotic diseases, oncology, monogenic diseases and metabolic disease. For more information, visit www.kadmon.com.
This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Help employers find you! Check out all the jobs and post your resume.
